FAS surged approximately 20% over the last 30 days, driven by a powerful rally in U.S. financial stocks amplified by the fund's 3x daily leverage. The quarterly trend is also strongly positive, with FAS gaining roughly 27% over the past three months.
FRMI closed down -10.38% to $5.87 during regular market hours. Previous close stood at $6.55, with the sharp decline occurring on elevated volume above 19 million shares.
The Amplify Cybersecurity ETF (HACK) surged approximately 19% over the past 30 days, driven by accelerating AI-related cybersecurity demand and strong earnings from its largest holdings. Over the last quarter, HACK gained roughly 40%, reflecting a powerful sector-wide rerating as enterprise security budgets expanded in response to increasingly sophisticated AI-powered threats.
TECL gained approximately 10.5% over the trailing 30-day period, recovering from a sharp mid-June technology selloff. The quarterly trend has been strongly positive, driven by a V-shaped recovery in technology equities from late-March lows and sustained AI infrastructure demand.
Disruptive innovation themes in genomics, fintech, and autonomous technologies remain central to ARKK’s positioning for long-term growth potential. Macro factors including interest rate trajectories and inflation trends could influence valuations of high-growth holdings across technology and healthcare sectors.
PENG is trading down -8.78% during the regular session on July 10, 2026, falling from a previous close of $81.39 to approximately $74.24. The decline follows an explosive two-day rally of over +30% after the company reported blockbuster Q3 earnings on July 7, with EPS of $0.84 beating estimates by 50% and revenue surging 48% year-over-year to $478.7M.
MRNA shares dropped -8.84% during regular trading on Friday, extending a sharp pullback from the 52-week high of $85.60 reached earlier this month. The sell-off continues the reversal that began after Morgan Stanley reiterated an Equal-Weight rating with a $39 price target, underscoring the wide gap between the stock's rally and near-term revenue expectations.
SPXL gained approximately 11% over the last 30 days, recovering from a mid-June low near $250 to trade above $277. The quarterly trend has been powerfully positive, with the fund benefiting from the S&P 500's strongest quarter in six years.
XBI surged approximately 27% over the past 30 days, driven by a powerful rotation into biotechnology stocks and a resurgence in mergers and acquisitions (M&A) activity. The equal-weighted structure of the fund amplified gains across small- and mid-cap biotech names, rather than concentrating returns in a few large-cap holdings.
IONS shares are down -7.47% during regular market trading on July 10, extending yesterday's massive -23.9% collapse following the failed CARDIO-TTRansform Phase 3 trial. The sell-off continues after Ionis and partner AstraZeneca announced the trial for eplontersen in ATTR cardiomyopathy missed its primary composite endpoint of cardiovascular mortality and recurrent CV events.
WD-40 Company shares are up approximately 16% in premarket trading after a blowout fiscal third-quarter earnings report. The primary catalyst is a massive earnings and revenue beat, with adjusted EPS of $2.33 versus a consensus estimate of $1.58, a surprise of more than 47%.
Circle Internet Group shares are indicated up approximately 13% in premarket trading, rebounding sharply from recent weakness. The primary catalyst appears to be a broad crypto-sector rally, with Bitcoin up roughly 10% in July on improving rate-cut expectations.
Shares of Fermi Inc. are down roughly 16% in premarket trading following news of a $375 million convertible senior notes offering. The primary catalyst is dilution concern tied to the upsized convertible debt sale, which offers conversion protection only up to $14.64 per share.
Price Target: $1,500 per share, representing approximately 51% upside from current levels near $992, is a widely discussed analyst target backed by several major Wall Street firms. Strongest Bullish Factors: AI-driven demand for high-bandwidth memory (HBM) has created a structural supply shortage, with Micron's HBM capacity sold out through 2027 and $100 billion in multi-year strategic customer agreements providing unprecedented revenue visibility.
The $130 price target represents a meaningful upside from Walmart's recent trading range around $113, with multiple Wall Street analysts setting price targets at or above this level. Strong bullish factors include Walmart's expanding high-margin businesses such as advertising and membership income, robust e-commerce growth, and consistent market share gains across income brackets.
The $800 price target represents roughly 33% upside from recent trading levels near $603, and is widely discussed among Wall Street analysts. Exceptional advertising revenue growth, with a 26% year-over-year increase in the most recent quarter, powered by AI-driven ad targeting and rising user engagement, is the strongest bullish catalyst.
Price target in focus: $1,400 represents a widely discussed analyst target and a logical next milestone for Eli Lilly and Company (LLY) , implying roughly 15% upside from recent levels near $1,215. Strongest bullish factors: An industry-leading portfolio of GLP-1 drugs, a historic $27 billion manufacturing expansion, and expanding insurance coverage are creating a powerful revenue flywheel.
Price Target: $250 represents the lowest Wall Street analyst target and a potential new all-time high above the 52-week peak of $236.54. Bullish Catalysts: Record data center revenue of $75.2 billion in Q1 FY2027, Blackwell architecture ramp, and projected hyperscaler AI capex reaching $1 trillion by 2027.
Hyatt Hotels Corporation is scheduled to report second quarter 2026 results on July 30, 2026, before market open. Analyst consensus estimates call for diluted EPS of approximately $0.92 and revenue near $1.81 billion.
Delta Air Lines is set to report second-quarter 2026 results on July 10, 2026, before market open. Consensus estimates point to adjusted earnings per share of approximately $1.48 to $1.49.